Status:
COMPLETED
Use of the Modified PUQE Score on Admitted Cases of Hyperemesis Gravidarum (HG) to Guide Response to Treatment
Lead Sponsor:
Tasnem Abo-elouon
Collaborating Sponsors:
Assiut University
Conditions:
Hyperemesis Gravidarum
Eligibility:
FEMALE
16-46 years
Brief Summary
Use of the PUQE score to judge the need for admission in cases of hyperemesis gravidarum Evaluation of the response to treatment by the PUQE score
Detailed Description
Nausea and nomiting of Pregnancy (NVP) affects up to 80% of pregnant women . Severe NVP is one of the most common indications for hospital admission among pregnant women, with typical stays of between...
Eligibility Criteria
Inclusion
- women hospitalized due to hyperemesis gravidarum with at least two out of three criteria; dehydration, weight loss \> 5% of prepregnancy weight (if known) or electrolyte imbalance/ketonuria.
- Gestational age between 6\_16 weeks.
Exclusion
- Women Suffered from other diseases causing nausea and vomiting :
- gastritis
- renal diseases
- Hepatic disorders
- Throid disorders
- the gestational length was more than 16 weeks at inclusion.
Key Trial Info
Start Date :
September 5 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04785911
Start Date
September 5 2021
End Date
November 1 2022
Last Update
April 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tasnem iIbrahem Aboelouon
Asyut, Assuit, Egypt, 71684